TScan Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · WALTHAM · MA
Moderate confidence (50%)
Updated Oct 14, 2026, 12:03 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: TScan Therapeutics, Inc. received a delisting notice from its exchange (Aug 27, 2026)
Timeline
Every material event, newest first. History is never overwritten.
TScan Therapeutics, Inc. received a delisting notice from its exchange
Aug 27, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, the Company received written notice (the Notice ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) stating that the Company s voting common stock, par value $0.0001 per share (the Common Stock ) failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Rule ) based upon the closing bid price of the Common Stock for the 3…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Biological Products, (No Diagnostic Substances)
- Subindustry
- —
- Listing
- SEC lists the ticker TCRX on Nasdaq.
- SEC CIK
- 0001783328
- Website
- ir.tscan.comVerified from SEC EDGAR · Sep 23, 2026
- —
- Headquarters
- WALTHAM, MA
- Also known as
- —
- Legal entities
- TScan Therapeutics, Inc.
Sources
Every material source used to build this profile.
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, the Company received written notice (the Notice ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) stating that the Company s voting common stock, par value $0.0001 per share (the Common Stock ) failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Rule ) based upon the closing bid price of the Common Stock for the 3…
View source recordSEC Company Submissions (TIER 1 · UNVERIFIED)
TScan Therapeutics, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — WALTHAM, MA
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:35 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:46 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 02:39 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.